Earth Science Tech (OTC: ETST) is a strategic holding company that builds value by acquiring and actively managing operating businesses in pharmaceuticals, telemedicine, healthcare services, real estate, and select consumer markets. The company focuses on controlling interests in subsidiaries where operational oversight, regulatory compliance, and disciplined scaling can drive durable growth.
Since 2022, Earth Science Tech has completed a deliberate transition away from legacy activities and repositioned the organization around healthcare and pharmaceutical operations. That shift has been supported by regulatory alignment, expanding operating capabilities, and the assembly of a diversified portfolio of revenue-generating businesses.
Today, the company’s approach emphasizes execution, capital discipline, and long-term value creation across its operating platforms, with a focus on scaling businesses that can grow sustainably while enhancing shareholder value.
The company is headquartered in Miami, Florida.
Subsidiaries
Earth Science Tech conducts its operations through a portfolio of wholly owned and majority-owned subsidiaries spanning pharmaceutical compounding, telemedicine, healthcare services, real estate development, and direct-to-consumer products.
Collectively, these subsidiaries provide Earth Science Tech with diversified exposure across regulated healthcare services, digital health platforms, real estate assets, and proprietary consumer brands.
Market Opportunity
Earth Science Tech is primarily positioned within the pharmaceutical compounding and telemedicine markets, both of which are experiencing sustained growth driven by demand for personalized healthcare solutions, expanded access to care, and increasing adoption of remote service models.
The pharmaceutical compounding market continues to benefit from rising demand for customized medications, improved patient adherence, and supply-chain flexibility. According to Grand View Research, the global compounding pharmacies market was valued at approximately $13.1 billion in 2023 and is projected to reach $18.6 billion by 2030, representing a compound annual growth rate of 5.11% from 2024 to 2030. Earth Science Tech’s compounding operations through RxCompoundStore.com and Mister Meds align directly with this expanding market segment.
Telemedicine represents a second core growth vertical for the company, supporting the clinical delivery of pharmaceutical products and healthcare services. According to Fortune Business Insights, the global telemedicine market was valued at $111.99 billion in 2025 and is projected to grow to $532.08 billion by 2034, reflecting a compound annual growth rate of 20.0%, with North America accounting for approximately 48% of market share in 2025. Platforms operated by Peaks Curative and DOConsultations participate directly in this rapidly expanding digital health ecosystem.
Additional exposure to specialty healthcare clinics and real estate development provides diversification alongside the company’s core pharmaceutical and telemedicine operations.
Leadership Team
Giorgio R. Saumat, Chief Executive Officer and Chairman of the Board, is an investor and entrepreneur with more than 20 years of experience investing in, operating, and advising private businesses, including founding CASAU Group, a private equity firm focused on real estate, and POINT96 Consulting, which provides strategic planning services to businesses and accredited investors.
Ernesto L. Flores, Chief Financial Officer, is a financial executive with over a decade of experience in accounting, taxation, and financial management, having held senior roles overseeing compliance and financial operations at logistics and investment firms.
Mario G. Tabraue, President and Chief Operating Officer, brings experience across real estate, maritime operations, and digital infrastructure and was instrumental in acquiring RxCompoundStore.com with the vision of scaling it into a nationally competitive pharmaceutical and telemedicine platform.
Christopher Rose, Chief Technology Officer, is a technology and automation executive who previously led enterprise-wide automation initiatives at a Fortune 100 company, delivering large-scale operational efficiencies and global process automation.
For more information, visit the company’s website at https://earthsciencetech.com.
NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN
Behçet’s disease is characterized by unpredictable flare-ups and periods of remission, making long-term management particularly…
The recent vaccine policy changes that the U.S. government announced have astounded experts because the changes reduce…
The normal practice after someone has undergone a surgical procedure has been to administer anti-inflammatory…
CTCL is recognized by clinicians as one of the most difficult cancers to diagnose accurately…
A new collaboration between Penn State College of Medicine and Targepeutics seeks to advance research into a promising combination…
Immunotherapy has emerged as a more gentle way to treat cancer over the past few years. However, it is…